Возможности коррекции дислипидемии у пациентов с артериальной гипертензией


А.С. Ермолаева, О.В. Дралова, О.Д. Остроумова, М.Л. Максимов

Кафедра клинической фармакологии и пропедевтики внутренних болезней ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава Росси, Москва
Представлены результаты исследования по изучению гипотензивной и гиполипидемичекой эффективности комбинированной антигипертензивной терапии ингибитором ангиотензинпревращающего фермента (иАПФ) фозиноприла в стартовой дозе 10 мг/сут, тиазидоподобным диуретиком индапамидом в стартовой дозе 1,5 мг/сут в сочетании с диетой или с добавлением симвастатина. Показано, что комбинированная терапия пациентов с дислипидемической гипертензией с использованием иАПФ и статина способна значительно снижать риск сердечно-сосудистых событий. Причем при равном антигипертензивном действии комбинация фозиноприла с симвастатином была значительно эффективнее терапии фозиноприлом в плане снижения риска основных сердечно-сосудистых осложнений. Усиление клинического эффекта при комбинации иАПФ со статинами, вероятнее всего, можно объяснить не синергизмом их гипотензивного или гиполипидемического эффекта, а взаимоусиливающим ангиопротективным действием.

Литература



  1. Оганов Р.Г., Тимофеева Т.Н., Колтунов И.Е., и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003–2010 гг. Кардиоваскулярная терапия и профилактика. 2011;1:9–13.

  2. ABC Of Hypertension,edited by Beevers D.G, Lip G.H. and O’Brien E. 5th ed. Malden, Mass: BMJ Books, 2007. Р. 88.

  3. Stamler J., Wentworth D., Neaton D. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension: Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am. J. Med. 1986;80:33–9.

  4. Alexander W.R. Hypertension and the Pathogenesis of Atherosclerosis. Hypertension. 1995;25:155–61.

  5. O’Donnell V.B. Free radicals and lipid signaling in endothelial cells. Antiox Redox Signal. 2003;5:195–203.

  6. Wolfrum S., Jensen K.S., Liao J.K. Endothelium-dependent effects of statins. Arterioscler Thromb. Vasc. Biol. 2003;23:729–36.

  7. Nakazono K., Watanabe N., Matsuno K., et al. Does superoxide underlie the pathogenesis of hypertension? Proc. Natl. Acad. Sci. U S A. 1991;88:10045–48.

  8. Сhobanian A.V. Clinical practice. Isolated systolic hypertension in the elderly. N. Engl. J. Med. 2007;357:789–96.

  9. Nofer J.R., Kehrel B., Fobker M., et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002;161:1–16.

  10. Cardillo C., Kilcoyne C.M., Cannon R.O., Panza J.A. Increased activity of endogenous endothelin in patients with hypercholesterolemia. J. Am. Coll.. Cardiol. 2000;36:1483–88.

  11. Working Group on Management of Patients with Hypertension and High Blood Cholesterol. National education programs working group report on the management of patients with hypertension and high blood cholesterol. Ann. Intern. Med. 1991;114:224.

  12. Wierzbicki A.S. Lipid lowering: Another method of reducing blood pressure? J. Hum. Hypertens. 2002;16:753–60.

  13. Sinha R., Dufour S., Petersen K.F., et al. Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes. 2002;51(4):1022–27.

  14. Johannsen D.L., Ravussin E. Can increased muscle ROS scavenging keep older animals young and metabolically fit? Cell. Metab. 2010;12(6):557–58.

  15. Preedy V.R., Adachi J., Asano M., et al. Free radicals in alcoholic myopathy: indices of damage and preventive studies. Free Radic. Biol. Med. 2002;32(8):683–87.

  16. Victor V.M., Rocha M., Herance R., et al. Oxidative stress and mitochondrial dysfunction in type 2 diabetes. Curr. Pharm. Des. 2011;17(36):3947–58.

  17. Morgado M., Rolo S., Macedo A.F., Castelo-Bran-co M. J. Cardiovasc. Dis. Res. 2011;2(1):44–9.

  18. Borghi C., Prandin G., Costa V., et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J. Cardiovasc. Pharmacol. 2000;35:549–55.

  19. Borghi C., Dormi A., Veronesi M., Sangiorgi Z., Gaddi A. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am. Heart J. 2004;148:285–92.

  20. Sorrentino S., Landmesser U. Nonlipid-lowering effects of statins. Curr Treat Options Cardiovasc. Med. 2005;7(6):459–66.

  21. Zhou Q, Liao JK. Pleiotropic effects of statins. - Basic research and clinical perspectives. Circ. J. 2010;74(5):818–26.

  22. Wang C.Y., Liu P.Y., Liao J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med. 2008;14(1):37–44.

  23. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–96.

  24. Koh K.K., Quon M.J., Rosenson R.S., et al. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int. J. Cardiol. 2008;124(2):149–59.

  25. Rawlings R., Nohria A., Liu P.Y., et al. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am. J. Cardiol. 2009;103(4):437–41.

  26. Liu P.Y., Liu YW, Lin L.J., et al. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009;119(1):131–38.

  27. Koh K.K., Quon M.J., Rosenson R.S., et al. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int. J. Cardiol. 2008;124(2):149–59.

  28. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999;340(6):448–54.

  29. Wang C.H., Li S.H., Weisel R.D., et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107(13):1783–90.

  30. Kleemann R., Verschuren L., de Rooij B.J., et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood. 2004;103(11):4188–94.

  31. Ferrario C.M., Richmond R.S., Smith R., et al. Reninangiotensin system as a therapeutic target in managing atherosclerosis. Am. J. Ther. 2004;11(1): 44–53.

  32. Yusuf S., Gerstein H., Hoogwerf B., et al. Ramipril and the development of diabetes. JAMA. 2001;286(15):1882–85.

  33. Barzilay J.I., Davis B.R., Cutler J.A., et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 2006;166(20):2191–201.

  34. Bosch J., Yusuf S., Gerstein H.C., et al. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 2006;355(15):1551–62.

  35. McMurray J.J., Holman R.R., Haffner S.M., et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 2010;362(16):1477–90.

  36. Van Linthout S., Spillmann F., Lorenz M., et al. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension. 2009;53(4):682–87.

  37. Olsen M.H., Wachtell K., Beevers G., et al. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens. 2009;27(3):567–74.

  38. Nishida Y., Takahashi Y., Nakayama T., et al. Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. Cardiovasc. Diabetol. 2010;9:38.

  39. Плисюк А.Г., Кулев Б.Д., Азизова О.А., и др.. Влияние комбинированной терапии лизиноприлом и симвастатином на эластические свойства крупных артерий у пациентов с артериаьной гипертензией и умеренной гиперлипидемией. Фарматека 2009;4:65–70.

  40. Strazzullo P., Kerry S.M., Barbato A., et al. Do statins reduce blood pressure? A meta-analysis of randomized controlled trials. Hypertension. 2007;49:792–98.

  41. Borghi C., Dormi A., Veronesi M., et al : Brisighella Heart Study Working Party Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am. Heart J. 2004;148:285–92.

  42. Sever P., et al. Potential synergy between lipidlowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur. Heart J. 2006;27:2982–88.

  43. Athyros V.G., et al. Effect of statins and ACE inhibitors alone in combination on clinicaloutcome in patients with coronary heart disease. J. Hum. Hypertens. 2004;11:781–88.

  44. Rodriguez-Porcel M., Lerman L.O., Herrmann J., et al. Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. Arterioscler. Thromb. Vasc. Biol. 2003;23:885–91.

  45. Nickenig G., Sachinidis A., Michaelsen F., et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 1997;95:473–78.

  46. Wang C.H., Li S.H., Weisel R.D., et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107:1783–90.

  47. Koh K.K., Ahn J.Y., Han S.H., et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J. Am. Coll. Cardiol. 2003;42:905–10.

  48. Fukai T., Siegfried M.R., Ushio-Fukai M., et al. Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Circ. Res. 1999;85:23–8.

  49. Аронов Д.М. Плеотропные эффекты статинов. РМЖ. 2001;9:2–7.

  50. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA Reductase inhibitors. Circulation. 1998;97(2):1129–35.

  51. Vita J.A., Yeung A.C., Winniford M., et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation. 2000;102(8):846–51.

  52. Acham V., Broadhead V., Malaki G. et al. Asymmetric dimethylarginine causes cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler. Thromb. Vasc. Biol. 2003;23:1455–59.

  53. Ridker P.M., Danielson E., Rifai N., Glynn R.J. Valsar tan, blood pressure reduction and Creactive protein: primary report of the ValMARC trial. J. Hypertens. 2006;48:73–9.

  54. Delles C., et al. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am. J. Hypertens. 2002;15(7 Pt 1):590–93.

  55. Paiva, H., et al. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J. Cardiovasc. Pharmacol. 2003;41(2):219–22.

  56. Zanchetti A., Crepaldi G., Gene Bond M., et al. Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis Principal Results of PHYLLIS – A Randomized Double-Blind Trial. Stroke. 2004;35:2807–12.


Об авторах / Для корреспонденции


А.С. Ермолаева – аспирант кафедры клинической фармакологии и пропедевтики внутренних болезней лечебногофакультета ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава РФ
О.В. Дралова – к.м.н., ассистент кафедры клинической фармакологии и пропедевтики внутренних болезней лечебного факультета ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава РФ; e-mail: olgadralova@rambler.ru
О.Д. Остроумова – д.м.н., проф. кафедры клинической фармакологии и пропедевтики внутренних болезней лечебного факультета ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава РФ
М.Л. Максимов – д.м.н., проф. кафедры клинической фармакологии и пропедевтики внутренних болезней лечебного факультета ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава РФ


Похожие статьи


Бионика Медиа